# A First in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of EDK060 in Adults With CMT1A.

> **NCT07140614** · PHASE1 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 28 (estimated)

## Conditions studied

- Charcot-Marie-Tooth Disease, Type 1A

## Interventions

- **DRUG:** EDK060, dose A
- **DRUG:** EDK060, dose B
- **DRUG:** EDK060, dose C
- **DRUG:** EDK060, dose D
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07140614
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-30
- **Primary completion:** 2028-02-25
- **Final completion:** 2028-02-26
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07140614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07140614, "A First in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of EDK060 in Adults With CMT1A.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07140614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*